UNSPSC 51111643: Ketotrexate

This classification denotes a folate antagonist with the molecular formula C21H27N7O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 504RN634MM, chemically known as n-(p-((2-(2-amino-1,4,5,6,7,8-hexahydro-5-methyl-4-oxo-6-pteridinyl)ethyl)amino)benzoyl)-l-glutamic acid but generally known as ketotrexate, which bears US NIH Compound Identifier 68691. European Medicines Agency schedules Ketotrexate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08378MIG.

UNSPSC 51111643 Ketotrexate is a Commodity code for a specific pharmaceutical product — the chemotherapy agent methotrexate — that state and local governments procure for use in public health facilities, correctional medical systems, and institutional healthcare settings. The code captures a single active pharmaceutical ingredient used primarily in oncology and rheumatology treatment protocols within state-operated hospitals, county detention facilities, and other government-run clinical environments. Ketotrexate procurement by these bodies is typically integrated into broader pharmacy supply contracts or standalone pharmaceutical RFPs that bundle multiple chemotherapy agents; the actual scope of work involves sourcing the product to specification, arranging delivery and storage compliance with controlled-substance handling rules, and maintaining supply continuity for inpatient and outpatient treatment programs.

The source material provided contains no recent state or local contract opportunities under this code. Without posted solicitations, issuing-body patterns, geographic concentration, or named opportunities to examine, the current procurement activity level for this specific pharmaceutical under UNSPSC 51111643 cannot be characterized.